Sakar Healthcare

Why is Sakar Healthcare Ltd falling/rising?

As of 12-Jun, Sakar Healthcare Ltd's stock price is at 824.10, reflecting a 2.62% increase. The stock has significantly outperformed the Sensex over various time frames, showing strong growth and bullish trends supported by increased investor participation.

As of 12-Jun, Sakar Healthcare Ltd's stock price is rising, currently at 824.10, reflecting an increase of 21.05 or 2.62%. This upward movement is supported by several factors. Over the past week, the stock has outperformed the benchmark Sensex, gaining 6.58% compared to the Sensex's 1.10%. In the last month, the stock has surged by 44.67%, while the Sensex has only increased by 1.04%. Year-to-date, Sakar Healthcare has shown remarkable growth of 101.39%, contrasting sharply with the Sensex's decline of 9.59%. <BR><BR>Additionally, the stock has demonstrated strong performance over longer periods, with a 163.63% increase over the past year and an impressive 466.20% rise over the last five years. Today's trading activity indicates that Sakar Healthcare is performing well, having outperformed its sector by 1.99%. The stock is also trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a strong bullish trend. Furthermore, there has been a notable increase in investor participation, with delivery volume rising by 12.35% against the 5-day average. This combination of strong performance metrics and rising investor interest contributes to the stock's upward trajectory.

Which are the latest news on Sakar Healthcare?

What does Sakar Healthcare do?

Sakar Healthcare Ltd is a Micro Cap company in the Pharmaceuticals & Biotechnology industry, incorporated in 2004 and publicly listed since 2015, reporting net sales of 71 Cr and a net profit of 11 Cr for March 2026. Key metrics include a P/E of 61.00 and a market cap of INR 1,847 Cr.

Overview:<BR>Sakar Healthcare Ltd operates in the Pharmaceuticals & Biotechnology industry and is categorized as a Micro Cap company.<BR><BR>History:<BR>Sakar Healthcare Limited was incorporated as a Private Limited Company on March 26, 2004, and was converted into a Public Limited Company on March 27, 2015. The latest quarterly results report net sales and profit for March 2026.<BR><BR>Financial Snapshot:<BR>Net Sales: 71 Cr (Quarterly Results - Mar 2026) <BR>Net Profit: 11 Cr (Quarterly Results - Mar 2026) <BR>Market Cap: INR 1,847 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 61.00 <BR>Industry P/E: 34 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.17 <BR>Return on Equity: 9.39% <BR>Price to Book: 5.58 <BR><BR>Contact Details:<BR>Address: 10/13 Nr MN Desai Petrol Pump, Sarkhej Bavla Highway Changodar Gujarat : 382213 <BR>Tel: 91-2717-250477 <BR>Email: info@sakarhealthcare.com <BR>Website: http://www.sakarhealthcare.com

How big is Sakar Healthcare?

As of 10th June, Sakar Healthcare Ltd has a market capitalization of 1,847.00 Cr, with recent net sales of 251.74 Cr and a net profit of 30.48 Cr. Shareholder's funds are 285.48 Cr, and total assets amount to 415.26 Cr.

As of 10th June, Sakar Healthcare Ltd has a market capitalization of 1,847.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest 4 quarters, Sakar Healthcare reported Net Sales of 251.74 Cr and a Net Profit of 30.48 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, with Shareholder's Funds amounting to 285.48 Cr and Total Assets of 415.26 Cr.

Who are in the management team of Sakar Healthcare?

The management team of Sakar Healthcare includes Sanjay S Shah (Chairman & Managing Director), Aarsh S Shah (Joint Managing Director), Ritaben S Shah (Whole-time Director), and three Independent Non-Executive Directors: Shailesh B Patel, Prashant C Srivastav, and Hemendrakumar C Shah. They oversee the company's operations and strategic direction.

The management team of Sakar Healthcare includes the following individuals:<BR><BR>1. **Sanjay S Shah** - Chairman & Managing Director<BR>2. **Aarsh S Shah** - Joint Managing Director<BR>3. **Ritaben S Shah** - Whole-time Director<BR>4. **Shailesh B Patel** - Independent Non-Executive Director<BR>5. **Prashant C Srivastav** - Independent Non-Executive Director<BR>6. **Hemendrakumar C Shah** - Independent Non-Executive Director<BR><BR>This team is responsible for overseeing the company's operations and strategic direction.

Who are the peers of the Sakar Healthcare?

Sakar Healthcare's peers include Kwality Pharma, Venus Remedies, Hikal, Indoco Remedies, NGL Fine Chem, Windlas Biotech, Amrutanjan Healt, Hester Bios, and Beta Drugs Ltd. Sakar Healthcare has an average management risk and a 1-year return of 165.81%, which is positive compared to its peers.

Peers: The peers of Sakar Healthcare are Kwality Pharma, Venus Remedies, Hikal, Indoco Remedies, NGL Fine Chem, Windlas Biotech, Amrutanjan Healt, Hester Bios, and Beta Drugs Ltd.<BR><BR>Quality Snapshot: Excellent management risk is observed at Venus Remedies and Amrutanjan Healt, while Average management risk is found at Kwality Pharma, Hikal, Indoco Remedies, Sakar Healthcare, NGL Fine Chem, Windlas Biotech, Hester Bios, and Beta Drugs Ltd, and the rest. Growth is rated as Good for Venus Remedies, Average for Sakar Healthcare, Kwality Pharma, and Beta Drugs Ltd, and Below Average for Hikal, Indoco Remedies, NGL Fine Chem, Windlas Biotech, and Hester Bios, and the rest. Capital Structure is Excellent for Kwality Pharma, Venus Remedies, NGL Fine Chem, Windlas Biotech, and Amrutanjan Healt, while Average is seen at Sakar Healthcare, and Below Average at Hikal, Indoco Remedies, and Hester Bios, and the rest.<BR><BR>Return Snapshot: Venus Remedies has the highest 1-year return at 269.84%, while Hikal has the lowest at -52.39%. Sakar Healthcare's 1-year return of 165.81% is significantly positive compared to its peers. Additionally, Windlas Biotech and Amrutanjan Healt have negative six-month returns.

Should I buy, sell or hold Sakar Healthcare Ltd?

Are Sakar Healthcare Ltd latest results good or bad?

Sakar Healthcare Ltd's Q4 FY26 results are strong, with a net profit of ₹11.02 crore (up 91.32%) and revenue of ₹71.10 crore (up 41.52%), alongside improved operating and profit margins. However, the high price-to-earnings ratio of 41 may raise concerns about valuation sustainability.

Sakar Healthcare Ltd's latest results for Q4 FY26 are quite impressive. The company reported a net profit of ₹11.02 crore, reflecting a remarkable year-on-year growth of 91.32%. Revenue also saw significant growth, reaching ₹71.10 crore, which is a 41.52% increase compared to the same quarter last year. <BR><BR>Moreover, the operating margin has reached an all-time high of 36.91%, indicating strong operational efficiency. The profit after tax (PAT) margin improved to 15.50%, which is up from the previous year, showcasing the company's ability to convert revenue into profit effectively.<BR><BR>Overall, the financial performance has been characterized by substantial growth in both revenue and profit, along with improved margins, which suggests that the results are indeed good. However, it's worth noting that the stock is trading at a high price-to-earnings ratio of 41, which raises questions about valuation sustainability. While the operational metrics are strong, investors should consider the elevated valuations and potential risks associated with high volatility in the stock.

Is Sakar Healthcare overvalued or undervalued?

As of November 27, 2025, Sakar Healthcare is considered very expensive and overvalued, with a PE Ratio of 42.16 and other key ratios significantly higher than industry norms, indicating it may not be a favorable investment despite strong recent performance.

As of 27 November 2025, Sakar Healthcare's valuation grade has moved from expensive to very expensive. This indicates that the company is currently overvalued. Key ratios supporting this assessment include a PE Ratio of 42.16, an EV to EBIT of 30.26, and a Price to Book Value of 2.72, all of which are significantly higher than industry norms.<BR><BR>In comparison to its peers, Sakar Healthcare's PE Ratio is notably higher than Sun Pharma's 37.62 and Cipla's 22.67, which are categorized as expensive and attractive, respectively. Additionally, the company's EV to EBITDA of 17.37 is also elevated compared to the industry average. Despite a strong performance relative to the Sensex over the past year, with a return of 27.04% versus the Sensex's 7.99%, the current valuation suggests that Sakar Healthcare may not offer a favorable investment opportunity at this time.

Is Sakar Healthcare technically bullish or bearish?

As of November 27, 2025, the technical trend is bullish with strong indicators like MACD and moving averages supporting this view, despite some mildly bearish signals from Dow Theory and OBV on the weekly chart.

As of 27 November 2025, the technical trend has changed from mildly bullish to bullish. The current stance is bullish with strong indicators supporting this view. The MACD is bullish on both the weekly and monthly time frames, and the moving averages on the daily chart confirm a bullish trend. The Bollinger Bands indicate a bullish condition on the monthly and mildly bullish on the weekly. The KST is also bullish on both time frames. However, the Dow Theory shows a mildly bearish signal on the weekly but is mildly bullish on the monthly, and the OBV reflects a similar mildly bearish stance on the weekly while being mildly bullish on the monthly. Overall, the strength of the bullish trend is reinforced by the positive performance against the Sensex over multiple time frames, particularly the 1Y and 5Y returns.

How has been the historical performance of Sakar Healthcare?

Sakar Healthcare has shown consistent growth over the past five years, with net sales increasing from 94.74 Cr in Mar'21 to 177.58 Cr in Mar'25, and profit after tax rising from 10.68 Cr to 17.50 Cr. The company's total assets also expanded significantly, from 115.04 Cr in Mar'20 to 415.26 Cr in Mar'25, indicating strong financial performance.

Answer:<BR>The historical performance of Sakar Healthcare shows a consistent growth trajectory in net sales and profitability over the past five years.<BR><BR>Breakdown:<BR>Sakar Healthcare's net sales have increased from 94.74 Cr in Mar'21 to 177.58 Cr in Mar'25, demonstrating a strong upward trend. Total operating income has followed a similar pattern, rising from 94.74 Cr in Mar'21 to 177.58 Cr in Mar'25. The company's total expenditure has also grown, reaching 127.90 Cr in Mar'25, up from 72.14 Cr in Mar'21, primarily driven by rising raw material costs and employee expenses. Operating profit (PBDIT) has improved significantly, from 22.60 Cr in Mar'21 to 49.68 Cr in Mar'25, indicating enhanced operational efficiency. Profit before tax has increased from 13.23 Cr in Mar'21 to 21.53 Cr in Mar'25, while profit after tax has risen from 10.68 Cr in Mar'21 to 17.50 Cr in Mar'25. The company's earnings per share (EPS) have also shown growth, climbing from 6.84 in Mar'21 to 7.97 in Mar'25. On the balance sheet, total assets have expanded from 115.04 Cr in Mar'20 to 415.26 Cr in Mar'25, reflecting robust growth in shareholder's funds and reserves. Overall, Sakar Healthcare has demonstrated a solid financial performance with increasing revenues, profits, and asset growth over the years.

Who are the top shareholders of the Sakar Healthcare?

The top shareholders of Sakar Healthcare include Sanjay S Shah with 45.6%, Tata Capital Healthcare Fund II at 10.52%, and Foreign Institutional Investors holding 13.61%. Individual investors own 15.94%, with no pledged promoter holdings or mutual fund investments.

The top shareholders of Sakar Healthcare include the promoters, with Sanjay S Shah holding the largest share at 45.6%. Additionally, Tata Capital Healthcare Fund II is the highest public shareholder, owning 10.52%. Foreign Institutional Investors (FIIs) hold a combined 13.61% of the company through four different FIIs. Individual investors collectively own 15.94% of the shares. There are no pledged promoter holdings, and mutual funds do not currently hold any shares in the company.

When is the next results date for Sakar Healthcare?

No Upcoming Board Meetings

Has Sakar Healthcare declared dividend?

No Dividend History Available